



Development of a High-Throughput Fluorescence Polarization Assay to Identify Novel Ligands of Glutamate Carboxypeptidase II

Journal of Biomolecular Screening
XX(X) 1–11
© 2012 Society for Laboratory
Automation and Screening
DOI: 10.1177/1087057112451924
<http://jbx.sagepub.com>

Glenda Alquicer¹, David Sedlák², Youngjoo Byun^{3,4}, Jiří Pavlíček¹,
Marigo Stathis⁵, Camilo Rojas⁵, Barbara Slusher⁵, Martin G. Pomper³,
Petr Bartůněk², and Cyril Bařinka¹

Abstract

Glutamate carboxypeptidase II (GCPII) is an important target for therapeutic and diagnostic interventions aimed at prostate cancer and neurologic disorders. Here we describe the development and optimization of a high-throughput screening (HTS) assay based on fluorescence polarization (FP) that facilitates the identification of novel scaffolds inhibiting GCPII. First, we designed and synthesized a fluorescence probe based on a urea-based inhibitory scaffold covalently linked to a Bodipy TMR fluorophore (TMRGlu). Next, we established and optimized conditions suitable for HTS and evaluated the assay robustness by testing the influence of a variety of physicochemical parameters (e.g., pH, temperature, time) and additives. Using known GCPII inhibitors, the FP assay was shown to be comparable to benchmark assays established in the field. Finally, we evaluated the FP assay by HTS of a 20 000–compound library. The novel assay presented here is robust, highly reproducible ($Z' = 0.82$), inexpensive, and suitable for automation, thus providing an excellent platform for HTS of small-molecule libraries targeting GCPII.

Keywords

fluorescence polarization, high-throughput screening, glutamate carboxypeptidase II, prostate-specific membrane antigen, metalloproteinase

Introduction

Current studies focused on glutamate carboxypeptidase II (GCPII) prove that this zinc-dependent membrane-bound metalloproteinase can serve as a target for the imaging and treatment of prostate cancer and neurologic disorders.^{1–3} GCPII expression pattern is mainly restricted to prostatic tissue and both the central and peripheral nervous systems, but is also present at lower levels in kidneys, small intestine, and neovasculature of solid tumors.^{4–7}

Since GCPII expression is highly elevated in metastatic prostate carcinoma, the enzyme is exploited as a membrane-bound marker for prostate cancer imaging and experimental therapy. In addition, animal models of various neuropathologies (e.g., ischemia, traumatic brain injury, neuropathic pain, amyotrophic lateral sclerosis, diabetic polyneuropathy, schizophrenia) suggest that GCPII inhibition is neuroprotective by increasing the concentration of its cognate substrate N-acetylaspartylglutamate (NAAG) while countering the buildup of excitotoxic glutamate.^{1,3,8–11}

¹Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

²Center for Chemical Genetics & CZ-OPENSREEN, Institute of Molecular Genetics, v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic

³Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

⁴College of Pharmacy, Korea University, Sejong-ro, Jochiwon-eup, Yeonggi-gun, Chungnam, South Korea

⁵The Brain Science Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA

Received Apr 18, 2012, and in revised form May 18, 2012. Accepted for publication May 21, 2012.

Supplementary material for this article is available on the *Journal of Biomolecular Screening* Web site at <http://jbx.sagepub.com/supplemental>.

Corresponding Author:

Cyril Bařinka, Institute of Biotechnology AS CR, v.i., Laboratory of Structural Biology, Vídeňská 1083, 14220 Prague 4, Czech Republic
Email: cyril.barinka@img.cas.cz

Given the therapeutic and diagnostic potential of GCPII, it is not surprising that broad interest from both academic and industrial laboratories has surfaced regarding the design and development of GCPII-specific ligands/inhibitors. Presently, the two major categories of GCPII-specific inhibitors that exist are either analogs of NAAG (the GCPII substrate) or derivatives of glutamic acid (the reaction product).^{12,13} Consequently, both the chemical space tapped by such compounds and the diversity of GCPII-specific compounds are limited. For example, NAAG- or glutamate-based inhibitors are highly polar substances, with mitigated penetration into the neuronal compartment. Hence, structure-activity relationship (SAR) studies aimed at modifying physicochemical characteristics of current inhibitor scaffolds have so far failed to produce any real improvements. Therefore, the high-throughput identification of GCPII-specific scaffolds that could facilitate movement across the blood-brain barrier (BBB) would prove to be an invaluable tool for future basic studies and GCPII-based therapeutics.

The availability of a highly efficient, low-cost, and robust assay is a prerequisite for successful high-throughput screening (HTS), yet no such an assay has been described for GCPII. Currently, the available in vitro assays used for GCPII activity and inhibitory studies can be divided into three categories; their principles, together with their advantages and disadvantages, are summarized in **Table 1**. The radioenzymatic assay, based on quantifying the hydrolysis of radiolabeled ³H-NAAG, was the first in vitro assay employed successfully for both monitoring GCPII activity and inhibition studies. Due to its high sensitivity and low false-positive rates, it is regarded as a mainstay assay in GCPII studies. On the other hand, the assay is time-consuming, generates hazardous waste, and is expensive with low- to medium-throughput capability.^{14,15} An enzyme-coupled GCPII assay is based on the quantification of free glutamate using a commercially available Amplex Red glutamic acid kit (Molecular Probes, Eugene, OR). The assay exploits a chain of coupled enzymatic reactions to deliver a fluorescent signal that is directly proportional to the amount of free glutamate released via NAAG hydrolysis by GCPII.^{16,17} With the detection limit of 10 nM and scalability to a nanoliter format, the assay is in principle suitable for an HTS. However, in addition to high costs, the major disadvantage is a high false-positive rate that is associated with (1) the presence of three additional enzymes in the reaction mixture, (2) fluorescence quenching, and (3) oxidation of tested compounds by hydrogen peroxide formed during the generation of fluorescence, which can lead to decreased H₂O₂ concentration and the fluorescence intensity. The third approach relies on the hydrolysis of a suitable (non-natural) GCPII substrate with the subsequent detection of reaction products by high-performance liquid chromatography (HPLC).^{17–20} Although this approach offers several

advantageous features (nonhazardous, sensitive, low false-positive rate), it is more suitable to low-throughput applications dealing with a limited number of samples.

Here we present the design, development, and validation of a fluorescence polarization (FP) assay that complements and expands the portfolio of in vitro assays for GCPII. In contrast to the aforementioned assays, the key advantages FP offers include homogeneity, affordability, safety, robustness of signal, adaptability to low volumes, and suitability for automation.²¹ These combined characteristics render the FP assay an excellent platform for HTS of small-molecule libraries targeting GCPII.

Materials and Methods

Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich (Steinheim, Germany).

Protein Expression and Purification

Cloning, expression, and purification of the extracellular part of human GCPII (rhGCPII; amino acids 44–750) were executed as previously described.²² The protein was over-expressed in S2 cells and purified using the following steps: concentration by tangential flow filtration (TFF; Millipore, Molsheim, France), ion-exchange chromatography (Q and SP Sepharose FF), affinity chromatography on Lentil-Lectin Sepharose, and size exclusion chromatography on a Superdex 200 column (all resins/columns from GE Healthcare Bio-Sciences, Upsala, Sweden). Purified rhGCPII (in final buffer 20 mM Tris-HCl, 150 mM NaCl, pH 8.4) was concentrated to 9 mg/mL and kept at –80 °C until further use.

Synthesis of the Fluorescent Tracer: TMR-X-Lys-urea-Glu (TMRGlu)

To a solution of Lys-Urea-Glu (**1**) (5.4 mg, 0.017 mmol) in dimethylformamide (DMF; 1.5 mL) was added the commercially available Bodipy TMR-X (5 mg, 0.0082 mmol), followed by triethylamine (0.040 mL, 0.285 mmol). The pH of the reaction mixture was 9.0. After stirring for 6 h at room temperature, the excess solvent was evaporated under reduced pressure. The residue was diluted with a mixture of acetonitrile/water (1% trifluoroacetic acid [TFA], 1 mL), and the crude material was purified by HPLC (Econosphere C18, 10 μm, 250 × 10 mm; retention time, 23.5 min; mobile phase, A = 0.1% TFA in H₂O, B = 0.1% TFA in CH₃CN; gradient, 0 min = 10% B, 30 min = 90% B; flow rate, 3 mL/min) to afford 3.2 mg (48%) TMR-X-Lys-urea-Glu (TMRGlu; **Fig. 1**).

¹H NMR (400 MHz, CD₃CN/D₂O) δ 7.83 (d, J = 5.2 Hz, 2H), 7.43 (s, 1H), 7.08 (d, J = 2.8 Hz, 1H), 7.01 (d, J = 5.2

Table 1. An Overview of Current Assays Used for Glutamate Carboxypeptidase II (GCPII)

Method	Principle	Detection Equipment	High Throughput
Radioactivity (separation)	The radiolabeled substrate (N-acetylaspartyl [³ H]glutamate substrate) is hydrolyzed by GCPII. The substrate and free glutamate (the reaction product) are separated by an ion exchange resin. Free [³ H]glutamate quantified by scintillation counting ^{14,15}	Scintillation counter	Limited (96-well plates)
HPLC-based methods or direct labeling of reaction products	Products of substrate hydrolysis detected either using HPLC (upon column separation) or as change in fluorescence/absorbance upon product derivatization ¹⁷⁻²⁰	Fluorometer/plate reader or HPLC	No
Amplex Red-Glutamic Acid Assay	GCPII incubated with substrate featuring C-terminal glutamate. Glutamic acid (the reaction product) is quantified via coupled enzymatic chain reactions. Glutamate levels inferred from a standard curve ^{16,17,26}	Fluorometer Microplate reader	Yes
Fluorescence polarization	Detects binding of a small fluorescent ligand to a larger protein using plan-polarized light. Competition binding determined as a decrease in the FP signal when an inhibitor is able to displace (or obstruct) the probe from the protein	Fluorescence polarization plate reader	Yes

FP, fluorescence polarization; HPLC, high-performance liquid chromatography.




Figure 1. The synthesis of the fluorescent probe TMR-X-Lys-urea-Glu (TMRGlu) by covalently binding a Bodipy TMR fluorophore to a urea-based glutamate carboxypeptidase II (GCPII) inhibitor. DMF, dimethylformamide; TEA, triethylamine.

Hz, 2H), 6.60 (d, $J = 2.8$ Hz, 1H), 4.08–4.15 (m, 2H), 3.85 (s, 3H), 3.03–3.08 (m, 4H), 2.64–2.72 (m, 2H), 2.45 (s, 3H), 2.20–2.31 (m, 3H), 2.20 (s, 3H), 2.11–2.15 (m, 1H), 1.88–1.94 (m, 2H), 1.68–1.73 (m, 2H), 1.56–1.61 (m,

2H), 1.23–1.39 (m, 8H), 1.12–1.18 (m, 2H). Electrospray ionization mass spectrometry (ESI-MS) calculated for $C_{39}H_{51}BF_2N_6O_{10}^+$; positive mode: $[M+H]^+$ 813.38, found 813.00; negative mode: $[M-H]^-$ 811.36, found 810.80.

FP Binding Experiments

All FP experiments were carried out in 30 μL of the assay buffer (100 mM Tris-HCl, 20 mM NaCl, pH 7.5) in black, flat-bottom, polystyrene 384-well microplates (Corning, Inc., New York, NY). The FP was determined using the multilabel reader EnVision (PerkinElmer, Waltham, MA) equipped with a Bodipy TMR optimized filter set (excitation polarization filter 531 nm and emission filter 595 nm). The FP values were calculated as mP units using the equation $mP = 1000 \times [(I_{\parallel} - (G \times I_{\perp})) / (I_{\parallel} + (G \times I_{\perp}))]$, where I_{\parallel} is the parallel intensity, I_{\perp} is the perpendicular intensity, and $G(\text{factor}) = 0.8$.

Binding experiments using a constant concentration of 20 nM TMRGlu and decreasing concentrations of GCPII (starting at 500 μM , twofold dilutions) were performed in triplicates to determine the concentration necessary to reach saturation binding and optimize the assay window. The FP signal was measured following a 30-min incubation of the GCPII/TMRGlu mixture. All experiments were carried out at room temperature. The concentration resulting in 50% response (EC_{50}) was calculated in GraphPad Prism 5 (GraphPad Software, La Jolla, CA) using the sigmoidal dose-response regression function.

pH Profile

The influence of pH on the assay performance was evaluated by using the optimized assay conditions and the following selection of 100 mM buffers: sodium citrate (pH 4–5), 2-(N-morpholino) ethanesulfonic acid (MES; pH 5.5–6.5), 3-(N-Morpholino)propanesulfonic acid (MOPS; pH 6.5–7.5), tris(hydroxymethyl)aminomethane (Tris; pH 7–9), and 2-(cyclohexylamino) ethanesulfonic acid (CHES; pH 8.6–10). TMRGlu was diluted to 20 nM (final concentration) in a solution containing 100 mM buffer (of required pH) and 50 mM NaCl. The probe solution was then titrated by increasing concentrations of GCPII. Both probe and GCPII working solutions were prepared in 100 mM buffer (+ 50 mM NaCl) suitable for a given pH range. Following the 30-min incubation of the GCPII/TMRGlu mixture, the FP was measured to identify the saturating GCPII:TMRGlu ratio for a given pH.

Inhibition Constants of Known Inhibitors

The performance of the FP assay was compared to established GCPII activity assays by determining inhibition constants of known GCPII inhibitors. To cover a wide range of inhibition potency, we selected the following inhibitors: glutamic acid ($IC_{50} = 0.5$ mM), quisqualate ($IC_{50} = 10$ μM), JHU-242 ($IC_{50} = 20$ nM), 2-(phosphonomethyl) pentanedioic acid (2-PMPA; $IC_{50} = 0.3$ nM), ARMP4 ($IC_{50} = 60$ pM), and DCIBzL ($IC_{50} = 10$ pM). Increasing

concentrations of tested inhibitors were incubated with 60 nM GCPII (in 20 μL) for 25 min at room temperature. Next, 10 μL TMRGlu (60 nM in assay buffer) was added to the GCPII/inhibitor mixture and incubated for 30 more min. The experiments were carried out four independent times in triplicates. FP was measured and the data analyzed using a sigmoidal dose-response regression function in the GraphPad Prism 5.

Effects of Additives

To evaluate their effects on the assay performance, we assayed common additives in quadruplicates. These included DMSO (25% v/v), acetonitrile (20% v/v), Triton X-100 (2% v/v), Tween-20 (2% v/v), and NaCl (2M). Various concentrations of individual additives (twofold dilutions) were mixed with a fixed GCPII concentration (120 nM) in a total volume of 20 μL . Following a 20-min incubation, 10 μL TMRGlu (60 nM) was added and FP measured 30 min later. Data were analyzed by one-way analysis of variance (ANOVA) using the GraphPad Prism 5.

HTS of a Chemical Library

Screening of a chemical library consisting of 20 000 compounds was carried out in black, flat-bottom 384-well microplates (Corning, Inc.). Protein and TMRGlu stock solutions were kept at 4 $^{\circ}\text{C}$ and protected from light before they were used in the screening. First, 20 μL of 60 nM GCPII in the assay buffer was dispensed by the Multidrop Combi (Thermo Scientific, Billerica, MA) liquid dispenser to the assay plates prior to compound addition. Library compounds stored in 384-polypropylene compound plates at 1 mM in 100% DMSO were transferred by the JANUS Automated Workstation (PerkinElmer) equipped with a 96-pin tool (V&P Scientific, Inc., San Diego, CA). The compound transfer by the robot was optimized such that 30 nL of the DMSO solution was transferred each time, resulting in the 1000 \times compound dilution in the assay plate and 1 μM final concentration. Following a 25-min incubation on the bench, 10 μL of 60 nM TMRGlu in the assay buffer was dispensed by a Multidrop and FP was determined 30 min later.

To achieve higher final concentrations of the library compounds, we subsequently carried out a second screen by pipetting 1.5 μL of compound stock solutions to reach the final concentration of 60 μM .

To check the quality of the assay between plates throughout the screening, we used two established competitive GCPII inhibitors—2-PMPA and JHU-242 with $IC_{50} = 300$ pM and 20 nM, respectively—as positive controls in duplicates on each of the screened plates. The autofluorescence of the compounds was assessed with a 535-nm excitation filter and a 590-nm emission filter by measuring the

fluorescence intensity of each compound of the chemical library. The data from the FP measurement were stored in the database and normalized by the b-score method²³ after the completion of the screen.

Radioenzymatic Counterscreen

Inhibitory activity of tested compounds yielding FP readouts below 70% of uninhibited (control) reactions was validated using the radioactivity-based assay adapted to a microplate format.¹⁵ The counterscreen incorporated the testing of duplicates at two inhibitor concentrations: 100 μ M and 10 μ M. To 5 μ L of each tested compound (final 100 μ M and 10 μ M), 10 μ L GCPII (40 pM final concentration) and 30 μ L Tris-HCl buffer (pH 7.4, 40 mM and CoCl₂ 1 mM) were added. The mixture was incubated for 15 min and then exposed to NAA[³H]G (30 nM in a total volume of 50 μ L) for 15 min at 37 °C. 2-PMPA (10 μ M; final) was selected as the positive control and 2% DMSO as the negative control. The reaction was stopped with 50 μ L ice-cold sodium phosphate buffer (pH 7.5, 0.1 M). An aliquot of the reaction mixture (90 μ L) was transferred to a 96-well spin column (Harvard Bioscience Massachusetts, Holliston, MA) containing AG1X8 ion-exchange resin; the plate was centrifuged at 900 rpm for 3 to 5 min using a Beckman GS-6R centrifuge (Beckman Coulter, Brea, CA) equipped with a PTS-2000 rotor. After washing with 1 M formic acid (2 \times 90 μ L to each column), an aliquot (200 μ L) from each well was transferred to a solid scintillator-coated 96-well plate (Packard, Meriden, CT) and dried to completion. The radioactivity corresponding to [³H]G was determined with a scintillation counter (counting efficiency 40%, Topcount NXT; Packard). The percentage of inhibition was calculated and compared with the percentage calculated from the FP assay.

Results and Discussion

TMRGlu Design and Synthesis

The synthesis of the fluorescence probe, designated TMRGlu, was accomplished by covalently attaching a Bodipy TMR fluorophore (Invitrogen, Carlsbad, CA) to a urea-based GCPII inhibitory scaffold described previously.^{24,25} The synthetic scheme is shown in **Figure 1**.

The design of TMRGlu has been guided by our prior structural and SAR studies. The GCPII-docking portion TMRGlu is based on a lys-urea-glu moiety that serves as a building block for a variety of GCPII inhibitors and imaging agents.^{22,26} The fluorophore moiety (Bodipy TMR) is connected to the urea functionality via a 19-Å-long linker. It has shown that the appropriate (minimal) linker length is an important characteristic for the probe design and is preferably longer than 20 Å for the distal fluorophore moiety to be




Figure 2. Saturation binding curve for glutamate carboxypeptidase II (GCPII)/TMR-X-Lys-urea-Glu (TMRGlu). In total, 20 nM TMRGlu has been titrated by increasing concentrations of GCPII and corresponding fluorescence polarization (FP) and fluorescence intensity (P channel) measured. The data were fitted using a dose-response inhibition model; EC₅₀ = 13 nM.

placed outside the entrance funnel so that it does not hinder probe binding.^{26–28} The Bodipy TMR fluorophore was selected because of (1) a high extinction coefficient and high fluorescence quantum yield and (2) a relatively long excited-state lifetime.

GCPII/TMRGlu Saturation Binding

Preliminary experiments with the free TMRGlu established the optimal concentration of the probe at 20 nM. This is the minimal probe concentration that can be reliably measured without significant interference from background fluorescence (data not shown).

The saturation binding kinetics was determined by titrating a fixed 20-nM concentration of TMRGlu with increasing concentrations of GCPII, with the equilibrium saturation curve shown in **Figure 2**. The data were fitted using a sigmoidal regression function and the binding constant calculated at 13 nM with the saturation reached at approximately twofold excess of GCPII over TMRGlu. It can be noted from **Figure 2** that the 2:1 GCPII:TMRGlu ratio offers an excellent assay window with Δ mP = 330 (the differential between free TMRGlu [50 mP] and the GCPII/TMRGlu complex [380 mP]). Since the saturation conditions of the assay require GCPII concentration at approximately 40 nM, the lower limit of the assay (i.e., the lowest inhibition constant that can be determined by this assay) is restricted to this concentration range (see Competitive Inhibitors—Dose Response).

In addition to an increase in the mP value, the formation of the GCPII/TMRGlu complex is accompanied by the substantial decrease in the fluorescence yield of the TMRGlu in

both P and S planes (**Fig. 2**). Apparently, upon binding to GCPII, TMRGlu fluorescence is quenched by interactions with the enzyme, although the mechanistic details are not known at present. The observed changes in the fluorescence intensity could be thus used as a complementary parameter during the screening process, where both fluorescence polarization and intensity can be monitored. However, we did not systematically use this effect in the analysis of the screening data, and the hit identification was carried out entirely using the data from fluorescence polarization. In addition, the intrinsic autofluorescence of the compound was identified as the main source of false-positive hits.

Assay Optimization—Temperature Stability, pH Dependence, and the Effect of Additives

To evaluate the robustness of the assay, we used the saturation conditions described above to assess the influence of time, temperature, pH, and several common additives on the assay performance. Upon the addition of the TMRGlu to twofold molar excess of GCPII, the mixture reached equilibrium (i.e., no change in mP or fluorescence intensity) after approximately 10 min, and the solution was stable for at least 24 h at both 4 °C and 20 °C (room temperature). These results are in concordance with our unpublished data suggesting that GCPII is stable in buffered solutions for over 1 day. On the basis of these results, we took an advantage of the observed GCPII stability and typically used a 1- to 5-h assay window for our HTS (see below).

The influence of pH was evaluated for pH values ranging from 4 to 10, with the choice of an appropriate 100-mM buffer for each of the defined pH intervals. The “optimal” saturation curves (i.e. with lower K_d values and saturation reached at lower concentrations of GCPII) were observed using the Tris-HCl buffer at pH range 7.0 to 9.0. For pH intervals 5.5 to 7.0 and 9.0 to 10.0, a higher GCPII/TMRGlu ratio (250 nM/20 nM and 500 nM/20 nM GCPII/TMRGlu for pH 5.5 and 10.0, respectively) was needed, but the saturation could be reached eventually. Finally, at pH values below 5.5, saturation could not be reached for any GCPII concentration included in the test (up to 500 nM). These results reflect previous studies determining the pH dependence on NAAG-hydrolyzing activity by GCPII, where the enzyme was shown to retain activity, with a sharp decrease in the rate of substrate hydrolysis at pH <5.5 and >9.0. It is likely that extreme pH values are associated with lower affinity of GCPII toward substrates/inhibitors as well as leading to the (partial) denaturation of the protein.^{20,29}

DMSO is often used as a solvent for small-molecule compounds in chemical libraries, especially in circumstances when a library is mainly composed of more lipophilic molecules with limited water solubility. In addition, nonionic detergents, various salts, and volatile organic

solvents can be added to stabilize reaction mixtures of tested compounds. Several of such compounds were tested for their influence on the assay performance, and the data are summarized in **Supplementary Figure S1**. DMSO had no significant effect on the mP values at saturation, even at the highest concentration (25% v/v). Similar results were obtained for Triton X-100 (up to 2% v/v), Tween-20 (up to 2% v/v), and acetonitrile (up to 20% v/v). In the case of sodium chloride, the addition of NaCl up to 0.6 M did not show any influence on the assay performance, whereas higher NaCl concentrations (0.6–2.0 M) led to a slight decrease in maximum mP values. Such decrease, however, does not restrict the assay window, and the assay can be carried out even at very high salt concentrations. An excellent assay compatibility with up to 25% DMSO provides a platform suitable for the screening of CNS-dedicated libraries, in which compounds with limited water solubility (high LogP values) are expected to predominate. Our FP assay can thus in principle be used to identify novel nervous system targeting leads.

Competitive Inhibitors—Dose Response

To benchmark our novel FP assay to established GCPII activity assays (mainly the radioactive assay that is the “standard assay” in the field; **Table 1**), we determined inhibition constants for several known competitive GCPII inhibitors and compared data to values available in the literature. Inhibitors were chosen to cover a wide range of inhibition constants from millimolar (e.g., L-glutamate) to subnanomolar (e.g., 2-PMPA). Inhibition curves of several representative inhibitors together with calculated IC_{50} values are shown in **Figure 3**. Overall, when using inhibitors that are around IC_{50} values of 10 to 20 nM or above, the data obtained by the FP assay are nearly identical to IC_{50} values that were earlier determined by the radioenzymatic or HPLC assays. The following values are the calculated IC_{50} s by our assay (numbers in parentheses are for published inhibition constants determined by radioenzymatic or HPLC assays): 0.87 mM (0.50 mM) for glutamic acid, 16.7 μ M (10 μ M) for quisqualate, and 19.2 nM (20 nM) for JHU242. In the case of competitive inhibitors with subnanomolar inhibition constants, IC_{50} values fell to the limit of the assay, which can be roughly defined as 50% of GCPII concentration used for the screening. For example, using 20 nM TMRGlu together with 40 nM GCPII, one can expect IC_{50} values at around 20 nM for all subnanomolar inhibitors. We confirmed these theoretical predictions testing several potent GCPII inhibitors, including DCIBzL (IC_{50} = 0.01 nM; radioactive assay), 2-PMPA (IC_{50} = 0.3 nM), and ARMP-4 (IC_{50} = 0.06 nM). The IC_{50} values determined by FP were 12.6 nM, 14.2 nM, and 28.8 nM, for DCIBzL, ARMP-4, and 2-PMPA, respectively. In summary, in the case of competitive GCPII inhibitors, the assay




Figure 3. Inhibition constant for competitive glutamate carboxypeptidase II (GCPII) inhibitors: (A) glutamic acid, (B) quisqualate, (C) JHU242, (D) 2-PMPA, (E) DCIBzL, and (F) ARMP-4. Inhibition constants of several known GCPII competitive inhibitors (spanning inhibition potencies from nM to mM) were determined using the fluorescence polarization assay (FP) and compared to IC₅₀ values reported in the literature that were determined using a radioenzymatic assays (RA). The results for both assays are comparable with the exception of subnanomolar GCPII inhibitors (panels E, F), for which IC₅₀ values are below the limit of the assay (i.e., roughly equal to 50% concentration of GCPII in the assay).

window fits into the range spanning low nanomolar (limit 20 nM) to millimolar affinities, which is adequate for an HTS of chemical libraries that typically yield hits with micromolar affinities. Once a medicinal chemistry program is established and more potent compounds are generated, one could then switch back to lower throughput yet more sensitive assays for accurately measuring IC₅₀ values of less than 20 nM.

Noncompetitive Inhibitors

In the case of competitive inhibitors, both molecules (probe and tested compound) bind to spatially overlapping sites of the enzyme in an exclusive manner. Consequently, the tested compound can either displace GCPII-bound probe (probe added first, tested compound later) or directly block probe binding (tested compound added first, probe subsequently). The latter setup was used in our HTS (see below).

In the case of noncompetitive (allosteric) inhibitors, an inhibitor, typically interacting with residues outside the specificity pocket of the enzyme, should be able to block formation of the GCPII/TMRGlu complex when added to

the enzyme prior to the probe. On the other hand, the inhibitor addition to the preformed GCPII/TMRGlu complex should not have any effect on measured FP. In theory thus, one can distinguish between competitive and noncompetitive inhibitor binding by simply reversing the additions of inhibitor and probe to the assay mixture.

To test these predictions experimentally, we used IBT-100, a noncompetitive GCPII inhibitor with an unknown mode of action that binds at the surface of GCPII at a distance approximately 20 Å from the active site (data not shown). The addition of IBT-100 to the preformed GCPII/TMRGlu complex did not elicit any changes (probe displacement) throughout the whole range of concentrations tested. On the other hand, preincubation of the inhibitor with GCPII prior to probe addition resulted in the “typical” inhibition profile with IC₅₀ = 22.2 μM (Fig. 4A). To the contrary, analogous experiments using quisqualate, a competitive GCPII inhibitor with similar potency (IC₅₀ = 10 μM), produced nearly identical inhibition curves in both experimental setups (Fig. 4B). Consequently, this single set of experiments (there are no other noncompetitive GCPII inhibitors known) suggests that the FP assay is suitable for




Figure 4. Fluorescence polarization (FP) assay allows distinguishing between the noncompetitive/allosteric (**A**) and competitive (**B**) mode of inhibition. Both noncompetitive and competitive inhibitors block the formation of the glutamate carboxypeptidase II (GCPII)/TMR-X-Lys-urea-Glu (TMRGlu), when the inhibitor is preincubated with the enzyme prior to the probe addition (empty circles; $IC_{50} = 22 \mu\text{M}$ and $IC_{50} = 46 \mu\text{M}$ for IBT-100 and quisqualate, respectively). A noncompetitive inhibitor, however, is unable to displace the probe when added to the preformed GCPII/TMRGlu complex (panel **A**, squares), whereas the addition of a competitive inhibitor to the preformed GCPII/TMRGlu complex is accompanied by a decrease in the FP value (panel **B**, squares; $IC_{50} = 12 \mu\text{M}$) as a result of the probe displacement by the inhibitor.

the identification of both competitive and noncompetitive (allosteric) inhibitors of GCPII as well as offers an easy way to distinguish between the two classes of inhibitors.

High-Throughput Screening

To determine relevant qualitative/quantitative assay statistics, we carried out five independent experiments using optimized assay conditions together with several known GCPII inhibitors as standards (data not shown). Considering both intra- and interplate variations, the calculated Z' factor is 0.82, validating the applicability of the assay for HTS applications.^{30,31}

We next used the validated assay for an HTS using several distinct small-molecule libraries comprising approximately 20 000 compounds. Libraries were screened at two final concentrations, 1 μM and 60 μM , respectively, as described earlier. The second (higher concentration) screen was required because using 1- μM concentrations of tested compounds (the first screen) yielded only a limited number of positive hits. 2-PMPA and JHU-242, two established competitive GCPII inhibitors with IC_{50} values of 300 pM and 20 nM, respectively, were used as internal positive standards throughout screening. A typical layout from a plate is shown in **Supplementary Figure S2**.

During our HTS, we noticed that many false-positive readings were associated with intensely colored compounds often yielding high background fluorescence. Such false-positive readings are, however, intrinsically linked with these types of assays and are difficult to fully eliminate.³¹

To minimize the impact of the inherent fluorescence of compounds on the fluorescence polarization readout, we have determined the autofluorescence of compounds in the library at similar excitation/emission wavelengths that were used for the fluorescence polarization (535/595 nm). Of the 10 strongest autofluorescent compounds, 9 were active in the HTS at both 1- μM and 60- μM concentrations, suggesting that beside dynamic/static quenching, the compound autofluorescence is one of the factors contributing to the false-positive determinations. Therefore, a careful choice of the cutoff for autofluorescent compound exclusion is needed to achieve good balance for specific hit identification and false-positive hit exclusion. We have eliminated all compounds with autofluorescence exceeding five times the background level from the hit list as autofluorescent, as shown in **Table 2**.

For hit identification, we have tested different conditions based on the percentage of probe displacement from the GCPII protein (**Fig. 5**). When using stringent conditions (percentage of displacement >75 %, mP <130), no hit was identified in a 1- μM screen. Almost half of the hits identified in the 60- μM screen were autofluorescent. When releasing the conditions below 50%, the hit rate in the nonfluorescent compounds increased considerably, as shown in **Table 2**.

Overall, out of approximately 20 000 compounds tested, we selected 98 compounds and validated the prospective hits using a radioenzymatic assay in a 96-well plate format.¹⁵ The radioenzymatic counterscreen was performed at concentrations of 100 μM and 10 μM in duplicates. Only compounds that inhibited GCPII enzymatic activity at least

Table 2. Hit Rates in the Primary High-Throughput Screen (HTS)

% of GCPII Binding ^a	mP	Number of hits at 1 μ M ^b	Number of hits at 60 μ M ^c	Autofluorescent Compounds ^d
>90%	<88	0	6	3
>75%	<130	0	12	5
>50%	<215	10	65	19
>30%	<281	15	119	28
>25%	<300	18	166	30

A library of nearly 20 000 compounds was screened and data were normalized with the b-score algorithm. GCPII, glutamate carboxypeptidase II.

^aHits were identified using different cutoffs based on the percentage of probe displacement from the GCPII protein according to mP values.

^bNumber of hits in the 1- μ M screen.

^cNumber of hits in the 60- μ M screen.

^dNumber of active compounds in the HTS showing at least 5 times higher autofluorescence than the background.




Figure 5. Overview of the primary high-throughput screening (HTS) carried out at 60 μ M. Data were stored in the database and normalized with the b-score algorithm. Different cutoffs represented by dotted lines were applied to identify hits: a: b-score = -39 (>90% of GCPII binding), b: b-score = -35 (>75% of GCPII binding), c: b-score = -17 (>50% of GCPII binding), d: b-score = -9 (>25% of GCPII binding). GCPII, glutamate carboxypeptidase II.

from 30% at 100 μ M were considered validated hits. As expected, the false-positive rate increases with the relaxation of cutoffs used in the hit selection in the primary screen, as shown in **Table 3**. For example, all three nonfluorescent compounds that exhibited mP <88 in the primary screen were validated in the secondary screen. On the other hand, only 26 of 39 hits that showed mP <215 in the primary screen were subsequently validated. Generally, relaxation of the cutoffs for hit selection allows for discovery of new scaffolds with relatively lower affinity to GCPII at the cost of a higher false-positive rate.

In conclusion, the FP-based assay presented here is an excellent alternative to established GCPII assays and offers many advantageous features that include it being nonhazardous, homogeneous, adaptable to low volumes, and time/cost-effective. The robustness of the assay is supported by solid statistics ($Z' = 0.82$), compatibility with common solvents, and a wide assay range that spans from low nanomolar to

Table 3. Validation of the Primary Hits in the Radiometric Counterscreen

% of GCPII Binding in the HTS	mP	Validated Compounds ^a	Nonvalidated Compounds ^b	% of False-Positive Hits ^c
>90%	<88	3	0	0
>75%	<130	6	1	14
>50%	<215	26	13	33
>30%	<281	36	37	51
>25%	<300	43	53	55

Nonfluorescent compounds active in the primary high-throughput screen (HTS) were assayed in the radiometric counterscreen. GCPII, glutamate carboxypeptidase II.

^aNumber of compounds showing at least 30% of GCPII inhibition.

^bNumber of compounds that inhibited GCPII from less than 30% in the radiometric counterscreen.

^cThe percentage of false-positive hits was calculated as a ratio of nonvalidated compounds and all compounds assayed in the radiometric screen that were selected from the primary HTS according to respective cutoffs.

millimolar concentrations of tested compounds. Thus, for the drug developmental purpose of identifying novel inhibitory scaffold leads, the FP assay is ideally suited for HTS of small-compound libraries.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ministry of Education, Youth and Sports of the Czech Republic (ME10031, LC06077); IRG (project number 249220); EMBO (installation grant #1978); and the IBT (AV0Z50520701) provided institutional support. Funding was also provided by National Institutes of Health (NIH) CA151838, MH080580, CA161056 and CA134675.

References

1. Barinka, C.; Rojas, C.; Slusher, B.; Pomper, M. Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer. *Curr. Med. Chem.* **2012**, *19*, 856–870.
2. Foss, C.A.; Mease, R.C.; Cho, S.Y.; Kim, H.J.; Pomper, M.G. GCPII Imaging and Cancer. *Curr. Med. Chem.* **2012**, *19*, 1346–1359.
3. Zhou, J.; Neale, J.H.; Pomper, M.G.; Kozikowski, A.P. NAAG Peptidase Inhibitors and Their Potential for Diagnosis and Therapy. *Nat. Rev. Drug Discov.* **2005**, *4*, 1015–1026.
4. Marmioli, P.; Slusher, B.; Cavaletti, G. Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System. *Curr. Med. Chem.* **2012**.
5. Rovenska, M.; Hlouchova, K.; Sacha, P.; Mlcochova, P.; Horak, V.; Zamecnik, J.; Barinka, C.; Konvalinka, J. Tissue Expression and Enzymologic Characterization of Human Prostate Specific Membrane Antigen and Its Rat and Pig Orthologs. *Prostate* **2008**, *68*, 171–182.
6. Sacha, P.; Zamecnik, J.; Barinka, C.; Hlouchova, K.; Vicha, A.; Mlcochova, P.; Hilgert, I.; Eckschlager, T.; Konvalinka, J. Expression of Glutamate Carboxypeptidase II in Human Brain. *Neuroscience* **2007**, *144*, 1361–1372.
7. Sokoloff, R.L.; Norton, K.C.; Gasior, C.L.; Marker, K.M.; Grauer, L.S. A Dual-Monoclonal Sandwich Assay for Prostate-Specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine. *Prostate* **2000**, *43*, 150–157.
8. Wozniak, K.M.; Rojas, C.; Wu, Y.; Slusher, B.S. The Role of Glutamate Signaling in Pain Processes and Its Regulation by GCP II Inhibition. *Curr. Med. Chem.* **2012**, *19*, 1323–1334.
9. Rahn, K.A.; Slusher, B.S.; Kaplin, A.I. Glutamate in CNS Neurodegeneration and Cognition and Its Regulation by GCPII Inhibition. *Curr. Med. Chem.* **2012**, *19*, 1335–1345.
10. Slusher, B.S.; Vornov, J.J.; Thomas, A.G.; Hurn, P.D.; Harukuni, I.; Bhardwaj, A.; Traystman, R.J.; Robinson, M.B.; Britton, P.; Lu, X.C.; et al. Selective Inhibition of NAALADase, Which Converts NAAG to Glutamate, Reduces Ischemic Brain Injury. *Nat. Med.* **1999**, *5*, 1396–1402.
11. Bander, N.H. Technology Insight: Monoclonal Antibody Imaging of Prostate Cancer. *Nat. Clin. Pract. Urol.* **2006**, *3*, 216–225.
12. Ferraris, D.V.; Shukla, K.; Tsukamoto, T. Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors. *Curr. Med. Chem.* **2012**, *19*, 1282–1294.
13. Tsukamoto, T.; Wozniak, K.M.; Slusher, B.S. Progress in the Discovery and Development of Glutamate Carboxypeptidase II Inhibitors. *Drug Discov. Today* **2007**, *12*, 767–776.
14. Robinson, M.B.; Blakely, R.D.; Couto, R.; Coyle, J.T. Hydrolysis of the Brain Dipeptide N-acetyl-L-aspartyl-L-glutamate: Identification and Characterization of a Novel N-acetylated Alpha-Linked Acidic Dipeptidase Activity from Rat Brain. *J. Biol. Chem.* **1987**, *262*, 14498–14506.
15. Rojas, C.; Frazier, S.T.; Flanary, J.; Slusher, B.S. Kinetics and Inhibition of Glutamate Carboxypeptidase II Using a Microplate Assay. *Anal. Biochem.* **2002**, *310*, 50–54.
16. Chen, Y.; Foss, C.A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J.J.; Castanares, M.; Lupold, S.E.; Babich, J.W.; Mease, R.C.; et al. Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. *J. Med. Chem.* **2008**, *51*, 7933–7943.
17. Plechanovova, A.; Byun, Y.; Alquicer, G.; Skultetyova, L.; Mlcochova, P.; Nemcova, A.; Kim, H.J.; Navratil, M.; Mease, R.; Lubkowski, J.; et al. Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity. *J. Med. Chem.* **2011**, *54*, 7535–7546.
18. Anderson, M.O.; Wu, L.Y.; Santiago, N.M.; Moser, J.M.; Rowley, J.A.; Bolstad, E.S.; Berkman, C.E. Substrate Specificity of Prostate-Specific Membrane Antigen. *Bioorg. Med. Chem.* **2007**, *15*, 6678–6686.
19. Kamga, I.; Ng, R.; Hosaka, M.; Berkman, C.E. High-Performance Liquid Chromatography Method for Detecting Prostate-Specific Membrane Antigen Activity. *Anal. Biochem.* **2002**, *310*, 125–127.
20. Barinka, C.; Rinnova, M.; Sacha, P.; Rojas, C.; Majer, P.; Slusher, B.S.; Konvalinka, J. Substrate Specificity, Inhibition and Enzymological Analysis of Recombinant Human Glutamate Carboxypeptidase II. *J. Neurochem.* **2002**, *80*, 477–487.
21. Jameson, D.M.; Croney, J.C. Fluorescence Polarization: Past, Present and Future. *Comb. Chem. High Throughput Screen.* **2003**, *6*, 167–173.
22. Barinka, C.; Mlcochova, P.; Sacha, P.; Hilgert, I.; Majer, P.; Slusher, B.S.; Horejsi, V.; Konvalinka, J. Amino Acids at the N- and C-termini of Human Glutamate Carboxypeptidase II Are Required for Enzymatic Activity and Proper Folding. *Eur. J. Biochem.* **2004**, *271*, 2782–2790.
23. Brideau, C.; Gunter, B.; Pikounis, B.; Liaw, A. Improved Statistical Methods for Hit Selection in High-Throughput Screening. *J. Biomol. Screen.* **2003**, *8*, 634–647.
24. Kozikowski, A.P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J.H.; Pshenichkin, S.; Wroblewski, J.T. Design of Remarkably Simple, yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase). *J. Med. Chem.* **2001**, *44*, 298–301.
25. Barinka, C.; Byun, Y.; Dusich, C.L.; Banerjee, S.R.; Chen, Y.; Castanares, M.; Kozikowski, A.P.; Mease, R.C.; Pomper, M.G.; Lubkowski, J. Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization. *J. Med. Chem.* **2008**, *51*, 7737–7743.
26. Zhang, A.X.; Murelli, R.P.; Barinka, C.; Michel, J.; Cocleaza, A.; Jorgensen, W.L.; Lubkowski, J.; Spiegel, D.A. A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules. *J. Am. Chem. Soc.* **2010**, *132*, 12711–12716.
27. Pavlicek, J.; Ptacek, J.; Barinka, C. Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance

- for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the Enzyme. *Curr. Med. Chem.* **2012**, *19*, 1300–1309.
28. Liu, T.; Nedrow-Byers, J.R.; Hopkins, M.R.; Berkman, C.E. Spacer Length Effects on In Vitro Imaging and Surface Accessibility of Fluorescent Inhibitors of Prostate Specific Membrane Antigen. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 7013–7016.
29. Hlouchova, K.; Barinka, C.; Klusak, V.; Sacha, P.; Mlcochova, P.; Majer, P.; Rulisek, L.; Konvalinka, J. Biochemical Characterization of Human Glutamate Carboxypeptidase III. *J. Neurochem.* **2007**, *101*, 682–696.
30. Roehrl, M.H.; Wang, J.Y.; Wagner, G. A General Framework for Development and Data Analysis of Competitive High-Throughput Screens for Small-Molecule Inhibitors of Protein-Protein Interactions by Fluorescence Polarization. *Biochemistry* **2004**, *43*, 16056–16066.
31. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J. Biomol. Screen.* **1999**, *4*, 67–73.